Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Physiologically based pharmacokinetic (pbpk) modeling to predict the drug-drug interaction between cerivastatin and cyclosporin a

  • At: 2014 FIP Congress in PSWC, Melbourne (Australia)
  • Type: Poster
  • By: KIM, Soo-Jin (RIKEN, Sugiyama Lab., Yokohama, Japan)
  • Co-author(s): Yoshikado, Takashi (RIKEN, Yokohama, Japan)
    Yao, Yoshiaki (Astellas Pharma Inc., Ibaraki, Japan)
    Sugiyama, Yuichi (RIKEN, Yokohama, Japan)
  • Abstract:

    [Background] Cerivastatin (CER) was withdrawn from a world market because of severe side effect, rhabdomyolysis. It has been reported that the maximum plasma concentration and AUC were greatly increased 5-fold and 4-fold, respectively, by the coadministration of cyclosporin A (CsA) compared with control. Therefore, the increase of systemic..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses